CDSCO Report: 53 Common Medicines, Including Paracetamol and Calcium Tablets, Fail Quality Check

The Central Drugs Standard Control Organization (CDSCO) has recently released its latest report, revealing that several commonly used medicines have failed the quality check. This revelation has raised concerns, as these medicines are frequently prescribed and used for everyday health issues. Among the drugs that did not meet quality standards are popular medicines like Paracetamol, Calcium, and Vitamin D tablets.

Key Medicines That Failed the Quality Test

One of the major drugs that failed the quality check is Pantocid, a tablet manufactured by Sun Pharma, widely used to treat acid reflux. In addition to Pantocid, other commonly used medications such as Calcium and Vitamin D supplements also failed to pass the quality test. These deficiencies raise concerns about the safety and effectiveness of these treatments.

Other failed medicines include Shelcal and Pulmocil injections, both used in the treatment of high blood pressure. The widely prescribed antibiotic Clavam 625 produced by Alkem Health Science, also failed the drug test, raising alarms among healthcare professionals and consumers.

List of Substandard Medicines Released by CDSCO

CDSCO's report also disclosed a list of fake, substandard, and misbranded drugs, medical devices, vaccines, and cosmetic products. Some of the notable medicines that failed include:

Pulmocil (Sildenafil Injection)
Pantocid (Pantoprazole Tablet IP)
Ursocol 300 (Ursodeoxycholic Acid Tablets, Indian Pharmacopoeia)

Ursocol 300, manufactured by Sun Pharma, failed the quality test and is commonly used for treating gallstones and certain liver diseases. Other medicines like **Telma H** (Telmisartan 40mg and Hydrochlorothiazide 12.5mg tablets IP) and Defcort 6 (Deflazacort tablets) also failed the quality check.

Implications and Concerns

The failure of these essential medicines raises significant concerns about the safety and reliability of commonly prescribed treatments. Patients who rely on these medications for critical health issues, such as high blood pressure, liver disease, and gallstones, are now at risk due to substandard quality.

The CDSCO's report calls for immediate action from pharmaceutical companies to ensure better quality control measures and for consumers to be cautious when using these medications.